Xinyi Biotech and Legend Star helped supply xenotransplantation technology startup Qihan Biotech with $25.5m to follow $7.8m raised last year.
China-based organ transplantation technology developer Qihan Biotech has received $25.5m in a series A-plus round featuring biotech product supplier Xinyi Biotechnology and Legend Star, a vehicle for conglomerate Legend Holdings, China Money Network has reported.
The round was led by CMB International Capital, a division of financial services firm China Merchants Bank, and included BC Capital Management, Sequoia Capital and North Light Venture Capital. Media reports suggest Legend Star and CMB International supplied $20m of the cash in August…